Tetanus antitoxin veterinary grade API is a purified equine-derived immunoglobulin fragment preparation directed against Clostridium tetani neurotoxin, tetanospasmin. Model designations TAT-VET-API-1500L for the sterile liquid concentrate and TAT-VET-API-LYO for the lyophilised plug are used to differentiate the primary packaging configurations for downstream manufacture of injections, tablets, capsules, powders, granules, premix and solutions. The liquid presentation is standardised to not less than 1,500 IU/mL unless otherwise stated on the label; the lyophilised presentation is reconstituted with water for injection before sterile filling or further processing. Because the active substance is an immunoglobulin fragment, potency is defined biologically by toxin-neutralising activity rather than chromatographic purity alone. Sterility is controlled per Ph. Eur. 2.6.1, and bacterial endotoxin limits are assigned on the basis of intended dose volume and target species.

Source species and pepsin-cleavage variants in veterinary immunoglobulins

Equine plasma remains the primary source material for veterinary tetanus antitoxin because horses can be hyperimmunised to generate high neutralising titres. After plasma pooling, the IgG is digested with pepsin under controlled pH to yield F(ab′)₂ fragments; removal of the Fc region reduces complement activation and the risk of anaphylactoid reactions in target species. The digestion is monitored by size-exclusion chromatography to maintain a consistent fragment profile, because deviations alter residual intact IgG and Fab fragment composition. Residual intact IgG and aggregates are removed by ammonium sulfate precipitation, depth filtration, and ultrafiltration/diafiltration against a formulation-compatible buffer. The F(ab′)₂ product has a lower molecular mass than intact IgG, approximately 100 kDa, which alters tissue distribution and renal clearance compared with unfractionated hyperimmune serum and human tetanus immune globulin, the latter being predominantly intact IgG. Batch-to-batch variance in equine plasma titre is managed by standardisation against the WHO International Standard for Tetanus Antitoxin using the toxin neutralisation method described in Ph. Eur. 0030.

Source plasma is collected from closed herds maintained under a health monitoring programme that includes testing for equine infectious anaemia, equine viral arteritis, and other specified agents. The plasma pool is held in quarantine before downstream processing. Viral reduction is achieved by pepsin digestion, low-pH treatment, and orthogonal filtration steps; the cumulative reduction claim is process-specific and must be validated against relevant model viruses. This distinguishes the biological API from chemically synthesised small-molecule active ingredients, which do not require adventitious-agent control.

For the sterile liquid presentation, the F(ab′)₂ concentrate is formulated in a buffer containing sodium chloride and a stabiliser such as glycine or sorbitol. The pH is adjusted to 6.0–7.5 before terminal sterilisation by filtration through 0.22 µm membranes; terminal steam sterilisation is unsuitable because immunoglobulins are thermolabile. After filtration, the solution is aseptically filled into siliconised Type I glass vials or multilayer plastic bags under Grade A conditions. For the lyophilised presentation, the bulk solution is filled and freeze-dried using a cycle with annealing above the glass transition temperature of the formulation; primary drying is performed below the collapse temperature. Residual moisture is controlled to ≤ 3% to avoid hydrolytic degradation. Reconstitution time is recorded as an in-process control because slow dissolution can indicate aggregate formation.

Why does gastric transit preclude oral antitoxin bioavailability?

Tetanus antitoxin is a protein-based active ingredient. When administered orally as a tablet, capsule, powder, granule, premix or solution, the F(ab′)₂ fragment is exposed to gastric acid and pepsin at pH 1.5–3.5; enzymatic hydrolysis reduces the molecule to peptides and amino acids before neutralising antibody fragments can be absorbed across the intestinal epithelium. Intact immunoglobulins do not undergo carrier-mediated transcellular absorption at nutritionally relevant rates, and the large molecular size prevents paracellular passage. The oral presentations in this product range must therefore be understood as process intermediates or non-systemic formulations; they do not provide systemic protection against tetanus unless a protective enteric or mucosal delivery system is explicitly validated. Published data for this specific configuration is limited, and no systemic bioavailability claim should be made for orally administered antitoxin API without an appropriate pharmacokinetic study in the target species.

The release specification matrix for the API is given below. Potency is the critical quality attribute and is expressed in International Units per millilitre or per vial against the WHO International Standard. Other acceptance criteria are aligned with Ph. Eur. 0030, Ph. Eur. 2.6.1, and Ph. Eur. 2.6.14.

For injections, the liquid API is diluted to target potency in an aseptic formulation suite, filtered through a 0.22 µm sterilising-grade membrane, and filled into single- or multi-dose containers. Dose volumes for horses and cattle are commonly developed from 1,500 IU prophylactic doses to 10,000 IU or higher for therapeutic use, but labelled dosing must be derived from target-species challenge data. The lyophilised API is reconstituted with water for injection to an osmolality adjusted to approximately 290–330 mOsm/kg for intramuscular administration. Aggregation, visible particles, and subvisible particle counts are monitored because they correlate with reduced potency and increased risk of adverse reactions. Production-scale filling lines for protein products are equipped with disposable flow paths and single-use mixers to reduce cleaning-validation burden; filling line stoppages should be evaluated for protein gel formation at the needle tip.

The product is used primarily for passive immunisation of horses, cattle, sheep, and goats in peracute tetanus risk scenarios such as deep puncture wounds, castration, docking, and contaminated surgical procedures. The intramuscular route is conventional; subcutaneous injection may be used where slower absorption is acceptable. Intravenous use of equine-derived F(ab′)₂ preparations requires specific formulation qualification and should not be assumed from the intramuscular label. Acute anaphylactoid reactions are possible, particularly after repeated exposure to equine protein, and emergency veterinary supervision is required.

When reconstitution temperature falls below 15°C, aggregate formation may accelerate

Reconstitution of lyophilised antitoxin at low temperature can prolong dissolution time and increase the formation of soluble aggregates. Best practice is to warm the diluent to 20–25°C before transfer and to avoid vigorous shaking; high-shear agitation generates foam and exposes the immunoglobulin fragments to interfacial stress. After reconstitution, the solution should stand for 10–15 minutes and then be inspected visually for particles. Subvisible aggregate measurements by light obscuration in accordance with Ph. Eur. 2.9.19 should meet the limits for injectable preparations: not more than 6,000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container for small-volume parenterals where specified. The lyophilised formulation should be held below its glass transition temperature during storage, typically 2–8°C, with excursions evaluated by stability protocol.

Potency assignment is performed by the toxin neutralisation test in mice, in which a fixed amount of standard antitoxin protects against a defined challenge of tetanus toxin. The assay is read at end point and calibrated against the WHO International Standard; results are expressed in International Units. The L+ dose of toxin is determined periodically to control challenge potency. Enzyme immunoassays may be used for in-process monitoring, but the final release method remains the in vivo toxin neutralisation test unless regulatory equivalence has been demonstrated. The statistical validity of the mouse assay is established according to the pharmacopoeial design, and batch release limits include a potency overage to accommodate biological assay variability.

Comparative release parameters against non-veterinary antitoxin preparations

Differences from other products are substantial. The veterinary API is usually a pepsin-digested F(ab′)₂ preparation; human tetanus immune globulin is predominantly intact IgG; tetanus toxoid vaccines are not antitoxin preparations and do not provide immediate neutralisation. The table below summarises mechanistic and practical distinctions relevant to batch release and clinical use.

For powders, granules and premix presentations, the API may be adsorbed onto a suitable carrier such as lactose monohydrate, maltodextrin, or silica, but the protein must be protected from moisture and mechanical shear. Dry blending is performed in low-shear tumble or V-blenders; high-shear granulation with water can denature the antibody fragments. If tablet or capsule dosage forms are required for local or experimental administration, dry granulation or direct compression with microcrystalline cellulose and croscarmellose sodium is preferred over wet granulation. Compression force must not exceed the formulation-specific limit at which the amorphous protein matrix undergoes pressure-induced aggregation; the limit is established by compact simulation studies. Enteric coating, if used, must be designed to release the active in the small intestine, but this does not guarantee systemic uptake of intact F(ab′)₂.

Low-shear blending introduces moisture-dependent potency drift in lyophilised powders

Residual moisture is the dominant factor controlling powder flow and blend uniformity in lyophilised immunoglobulin formulations. Published stability data for lyophilised immunoglobulin formulations indicate that when the API is equilibrated above 40% relative humidity, the powder becomes cohesive and potency loss can exceed 10% after 24 hours at 25°C in unprotected handling conditions. Blending is therefore conducted in climate-controlled rooms at 20–25°C and ≤ 30% relative humidity. Near-infrared spectroscopy is used for blend uniformity, and the acceptance criterion for the lyophilised API particle size distribution is set according to the intended manufacturing route. Batch-to-batch differences in source plasma titre can shift the protein-to-carrier ratio; standardisation to fixed potency per gram is managed by adjusting the carrier mass.

Aluminum-adjuvanted toxoid vaccines cannot be syringe-mixed with antitoxin

Tetanus antitoxin must not be mixed in the same syringe or same injection site with aluminum-adjuvanted tetanus toxoid vaccines. The adjuvanted vaccine contains aluminum salts; the high ionic strength and pH of the antitoxin formulation can destabilise the adjuvant gel, causing aggregation. Conversely, vaccine excipients may induce precipitation of the immunoglobulin fragments. Separate injection sites and syringes are required. If simultaneous administration is clinically indicated, the antitoxin is given in one site and the vaccine in another, and the attending veterinarian records the product batch numbers. No compatibility data supports mixing of these two biological product classes in a single container.

Regulatory release of this API is performed under 21 CFR 211 for finished pharmaceuticals or the equivalent current good manufacturing practice for active substances. Batch release documentation includes the source herd health status, viral safety testing, and the potency release test. The API is of biological origin and must be handled under a documented biosecurity and biosafety risk assessment, typically assigned to biosafety level 1–2 depending on the country-specific regulatory classification. Stability under the approved storage condition is confirmed by ongoing long-term and accelerated protocols that measure potency, pH, moisture, and particulate matter.